Abraham Tacang, MD
Rheumatology · Crestview Hills, KYNPI 1336403914
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 375 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 37 manufacturers, the largest accounting for just 19.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $5,489, 5.6 times the $976 reported in 2019.
Across 375 payments — averaging $23.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- UCB, Inc.$1K
- Amgen$1K
- Novartis$957
- Johnson & Johnson$764
- ANI Pharmaceuticals, Inc.$659
- plus $3K from 31 others
What the payments were for
- Food & beverage$8,861100%
- Education$150%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 78 | $1,758 |
| UCB, Inc. | 42 | $1,124 |
| Amgen(2 entities) | 56 | $1,014 |
| Novartis | 43 | $957 |
| Johnson & Johnson | 30 | $764 |
| ANI Pharmaceuticals, Inc. | 21 | $659 |
| Mallinckrodt Hospital Products Inc. | 14 | $310 |
| GSK | 14 | $284 |
| Boehringer Ingelheim | 5 | $281 |
| Pfizer | 9 | $278 |
| AstraZeneca(2 entities) | 7 | $261 |
| E.r. Squibb & Sons, L.L.C. | 10 | $156 |
| Sanofi | 2 | $151 |
| Kyowa Kirin, Inc. | 2 | $135 |
| Lilly USA, LLC | 8 | $124 |
| Genentech USA, Inc. | 4 | $68 |
| Fresenius Kabi USA, LLC | 3 | $63 |
| Radius Health, Inc. | 4 | $62 |
| Aurinia Pharma U.S., Inc. | 2 | $49 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $46 |
| Exact Sciences | 2 | $43 |
| Regeneron Healthcare Solutions, Inc. | 1 | $33 |
| Organon | 1 | $27 |
| Grifols USA, LLC | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Si-bone, Inc. | 1 | $21 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Shire North American Group Inc | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Sobi, Inc | 1 | $14 |
| Daiichi Sankyo Inc. | 1 | $13 |
| Merck | 1 | $13 |
| Bayer | 1 | $12 |
| Hikma Pharmaceuticals USA | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rinvoq$389
- Tremfya$380
- Bimzelx$357
- PURIFIED CORTROPHIN GEL$271
- Skyrizi$130
- Otezla$122
- BENLYSTA$122
- KEVZARA$119
- Tavneos$105
- SIMPONI ARIA$103
How this compares
$8,876 in reported general payments places this provider in the 75th percentile of 81 rheumatology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 42 | $268,426 |
| Enbrel SureclickEtanercept | 33 | $228,930 |
| RinvoqUpadacitinib | 29 | $160,654 |
| Orencia ClickjectAbatacept | 31 | $143,575 |
| Cimzia (2 Pack)Certolizumab Pegol | 20 | $113,881 |
| EnbrelEtanercept | 13 | $95,210 |
| Humira(Cf)Adalimumab | 14 | $93,403 |
| BenlystaBelimumab | 22 | $92,219 |
| OtezlaApremilast | 12 | $57,524 |
| Actemra ActpenTocilizumab | 15 | $37,709 |
| Hydroxychloroquine Sulfate | 234 | $8,424 |
| Cevimeline Hcl | 33 | $6,609 |
| Colchicine | 35 | $4,220 |
| Leflunomide | 97 | $4,156 |
| MethotrexateMethotrexate Sodium | 167 | $2,717 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira(Cf) | $1,758 | $254,05743 claims |
| AmgenEnbrel, Otezla | $1,014 | $152,73325 claims |
| UCB, Inc.Cimzia (2 Pack) | $1,124 | $113,88120 claims |
| GSKBenlysta | $284 | $92,21922 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 81 rheumatology providers in Kentucky.
Other rheumatology in Crestview Hills
- Liza VargheseCrestview Hills$29K
- Christopher ColglazierCrestview Hills$22K
- Kerrin BurteCrestview Hills$16K
- Ann GeorgeCrestview Hills$8K
- Magdalena WiniarskaCrestview Hills$5K
- Mazen ElyanCrestview Hills$4K
- Sarah KellerCrestview Hills$3K
- Joseph TemmingCrestview Hills$2K
- Nicola JacksonCrestview Hills$2K
- Zehra KazmiCrestview Hills$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.